SecurityLMB / Limbach Holdings, Inc. (53263P105)
President and CEOBacon Charles A. III
IndustryConstruction Special Trade Contractors
Institutional Owners24
Institutional Shares2,309,667 - 30.62%
Common Stock Shares Outstanding7,542,249 shares (as of 2018-03-31)
Institutional Value$ 28,265,000 USD
Related TFSC / 1347 Capital Corp.
LMBH / Limbach Holdings, Inc
LMBHW / Limbach Holdings, Inc

Institutional Stock Ownership and Shareholders()

LMB / Limbach Holdings, Inc. Institutional Ownership

Limbach Holdings, Inc. (NASDAQ:LMB) has 24 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,309,667 shares. Largest shareholders include State of New Jersey Common Pension Fund D, Dimensional Fund Advisors Lp, Perritt Capital Management Inc, Arbor Wealth Management, LLC, Legato Capital Management LLC, Argent Capital Management Llc, Vanguard Group Inc, Acuitas Investments, Llc, New Jersey Better Educational Savings Trust, and NJ State Employees Deferred Compensation Plan.
Limbach Holdings, Inc. (NASDAQ:LMB) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href=""><img src="" alt="LMB / Limbach Holdings, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-05-15 13F-HR VANGUARD GROUP INC 19,831 108,444 446.84 275 1,342 388.00
2018-05-14 13F-HR MORGAN STANLEY 2,005 0 -100.00 28 0 -100.00
2018-07-11 13F-HR Mesirow Financial Investment Management, Inc. 37,093 21,199 -42.85 453 251 -44.59
2018-05-08 13F-HR State of New Jersey Common Pension Fund D 644,000 644,000 0.00 8,907 7,973 -10.49
2018-05-14 13F-HR ACK Asset Management LLC 200,000 0 -100.00 2,766 0 -100.00
2018-05-15 13F-HR UBS Group AG 0 4,763 0 58
2018-05-14 13F-HR NEXT CENTURY GROWTH INVESTORS LLC 143,614 0 -100.00 1,986 0 -100.00
2018-05-14 13F-HR Renaissance Technologies LLC 0 13,500 0 165
2018-05-03 13F-HR ARGENT CAPITAL MANAGEMENT LLC 111,180 1,359
2018-05-15 13F-HR PERRITT CAPITAL MANAGEMENT INC 288,050 285,050 -1.04 3,984 3,572 -10.34
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 447,839 458,904 2.47 6,194 5,681 -8.28
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 2,158 0 -100.00 30 0 -100.00
2018-05-15 13F-HR CWA Asset Management Group, LLC 12,680 11,380 -10.25 175 139 -20.57
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 90 8,061 8,856.67 1 99 9,800.00
2018-04-23 13F-HR SILVER CAPITAL MANAGEMENT LLC 14,236 38,686 171.75 197 189 -4.06
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 4,132 2,716 -34.27 57 33 -42.11
2018-05-07 13F-HR Acuitas Investments, Llc 50,060 620
2018-05-15 13F-HR LPL Financial LLC 41,240 42,540 3.15 570 520 -8.77
2018-05-09 13F-HR BlackRock Inc. 9,512 9,272 -2.52 132 113 -14.39
2018-04-26 13F-HR ESSEX INVESTMENT MANAGEMENT CO LLC 21,077 18,394 -12.73 291 225 -22.68
2018-04-20 13F-HR Steward Partners Investment Advisory, Llc 8,846 9,724 9.93 122 118 -3.28
2018-05-11 13F-HR MACQUARIE GROUP LTD 8,100 17,906 121.06 112 219 95.54
2018-05-17 13F-HR Arbor Wealth Management, LLC 80,308 213,553 165.92 1,110 2,695 142.79
2018-05-15 13F-HR DEUTSCHE BANK AG\ 6,800 11,100 63.24 94 135 43.62
2018-04-30 13F-HR New Jersey Better Educational Savings Trust 48,000 46,000 -4.17 664 569 -14.31
2018-05-02 13F-HR NJ State Employees Deferred Compensation Plan 42,000 43,000 2.38 581 532 -8.43
2018-07-11 13F-HR Legato Capital Management LLC 140,005 140,005 0.00 1,711 1,655 -3.27
2018-05-15 13F-HR Advisor Group, Inc. 230 3

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

9h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

11h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Limbach Holdings, Inc (LMB) CEO Charlie Bacon on Q1 2018 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Limbach Holdings, Inc. (NASDAQ:LMB) Q1 2018 Results Earnings Conference Call May 16, 2018 9:00 AM ET (1-1)

Limbach Holdings, Inc 2018 Q1 - Results - Earnings Call Slides

2018-05-16 seekingalpha
The following slide deck was published by Limbach Holdings, Inc in conjunction with their 2018 Q1 earnings call. (1-0)

How to Create a Winning Portfolio From Top-Ranked Industries

2018-05-10 zacks
Trump’s latest announcement of pulling out United States from the Obama-era Iran deal and reimposing powerful sanctions on the OPEC nation didn’t roil the stock market as expected. Then again, rising yields, a strengthening dollar and geopolitical uncertainty are continuously threatening the nine-year bull run. Amid widespread volatility, it is difficult to make wise investment decisions. As such, honing in on corners of the market that are expected to outperform could serve us better. (9-0)

Top Ranked Momentum Stocks to Buy for April 24th

2018-04-24 zacks
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 24th: (5-0)

Top Ranked Momentum Stocks to Buy for April 20th

2018-04-20 zacks
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th: (3-0)

CUSIP: 53263P105